Today's Date: January 20, 2021
More Florida Publix Pharmacies to Provide COVID-19 Vaccinations   •   First Cohort of Black Corporate Board Readiness Professionals Convenes at Santa Clara University   •   Women in Capital Markets Relaunches Return to Bay Street Program to Support Women Re-Entering the Finance Industry   •   P&G Announces Fiscal Year 2021 Second Quarter Results   •   New Hallo Report Finds Just 40 Black Founders Raised Venture Capital in Q4 2020   •   HITN Broadcasts Live Coverage of Inauguration Day 2021   •   Biden-Harris Administration Must Make Hunger a Priority in its First 100 Days   •   U.S. Mayors Celebrate President Biden's Day One Focus on Rooting Out Systemic Racism and Supporting Underserved Communities   •   A Multicultural America Ushers in Joseph R. Biden, Jr. As 46th President of the United States   •   Channing Martin Jones Appointed CSG’s First Chief Diversity and Social Responsibility Officer   •   Harmony Senior Services Recognizes Tony Sanford for Exceptional COVID-19 Management   •   Boss Nation Brands, Inc. Gets National Recognition for Charitable Giving   •   Fragrance Creators Association President & CEO Farah K. Ahmed's Statement on the Inauguration of President Joseph R. Biden a   •   Facedrive Welcomes Susan Uthayakumar, Schneider Electric’s Global Sustainability Leader, as Newest Advisory Board Member   •   Government of Canada COVID-19 Update for Indigenous Peoples and communities   •   MillionaireMatch Pushes Back Against False Claims That It Is for “Sugar Daddies”   •   Nationally Recognized Diversity and Inclusion Expert Jennifer Brown to Host “Leading Inclusively in times of Crisis and Be   •   Four Corners Oil And Gas Community Steps Up And Provides COVID19 Supplies And Scholarships To Local Native American Communities   •   Save the Storks' Statement on the Anniversary of Roe v. Wade and National Sanctity of Human Life Day   •   MetroPlusHealth Announces President and Chief Executive Officer Talya Schwartz, MD, Honored Again by City & State as One of
Bookmark and Share

CHOP and Penn Researchers Identify Nanoparticles that Could Be Used in Therapeutic mRNA Delivery before Birth

CHOP and Penn Researchers Identify Nanoparticles that Could Be Used in Therapeutic mRNA Delivery before Birth

--Study demonstrates the efficacy and therapeutic potential of select ionizable lipid nanoparticles for delivering mRNA to treat genetic diseases before birth--

PR Newswire

PHILADELPHIA, Jan. 13, 2021 /PRNewswire/ -- Researchers at Children's Hospital of Philadelphia and the School of Engineering and Applied Science at the University of Pennsylvania have identified ionizable lipid nanoparticles that could be used to deliver mRNA as part of fetal therapy. The proof-of-concept study, published today in Science Advances, engineered and screened a number of lipid nanoparticle formulations for targeting mouse fetal organs and has laid the groundwork for testing potential therapies to treat genetic diseases before birth.

"This is an important first step in identifying nonviral mediated approaches for delivering cutting-edge therapies before birth," said co-senior author William H. Peranteau, MD, an attending surgeon in the Division of General, Thoracic and Fetal Surgery and the Adzick-McCausland Distinguished Chair in Fetal and Pediatric Surgery at CHOP. "These lipid nanoparticles may provide a platform for in utero mRNA delivery, which would be used in therapies like fetal protein replacement and gene editing."

Michael J. Mitchell, Skirkanich Assistant Professor of Innovation in Penn Engineering's Department of Bioengineering, is the other co-senior author of the study.

Recent advances in DNA sequencing technology and prenatal diagnostics have made it possible to diagnose many genetic diseases before birth. Some of these diseases are treated by protein or enzyme replacement therapies after birth, but by then, some of the damaging effects of the disease have taken hold. Thus, applying therapies while the patient is still in the womb has the potential to be more effective for some conditions. The small fetal size allows for maximal therapeutic dosing, and the immature fetal immune system may be more tolerant of replacement therapy.

Of the potential vehicles for introducing therapeutic protein replacement, mRNA is distinct from  other nucleic acids, such as DNA, because it does not need to enter the nucleus and can use the body's own machinery to produce the desired proteins. Currently, the common methods of nucleic acid delivery include viral vectors and nonviral approaches. Although viral vectors may be well-suited to gene therapy, they come with the potential risk of unwanted integration of the transgene or parts of the viral vector in the recipient genome. Thus, there is an important need to develop safe and effective nonviral nucleic acid delivery technologies to treat prenatal diseases.

In order to identify potential nonviral delivery systems for therapeutic mRNA, the researchers engineered a library of lipid nanoparticles, small particles less than 100 nanometers in size that effectively enter cells in mouse fetal recipients. Each lipid nanoparticle formulation was used to encapsulate mRNA, which was administered to mouse fetuses. The researchers found that several of the lipid nanoparticles enabled functional mRNA delivery to fetal livers and that some of those lipid nanoparticles also delivered mRNA to the fetal lungs and intestines. They also assessed the lipid nanoparticles for toxicity and found them to be as safe or safer than existing formulations.

Having identified the lipid nanoparticles that were able to accumulate within fetal livers, lungs, and intestines with the highest efficiency and safety, the researchers also tested therapeutic potential of those designs by using them to deliver erythropoietin (EPO) mRNA, as the EPO protein is easily trackable. They found that EPO mRNA delivery to liver cells in mouse fetuses resulted in elevated levels of EPO protein in the fetal circulation, providing a model for protein replacement therapy via the liver using these lipid nanoparticles.

"A central challenge in the field of gene therapy is the delivery of nucleic acids to target cells and tissues, without causing side effects in healthy tissue. This is difficult to achieve in adult animals and humans, which have been studied extensively. Much less is known in terms of what is required to achieve in utero nucleic acid delivery," said Mitchell. "We are very excited by the initial results of our lipid nanoparticle technology to deliver mRNA in utero in safe and effective manner, which could open new avenues for lipid nanoparticles and mRNA therapeutics to treat diseases before birth."

Riley RS, Kashyap MV, Billingsley MM, White B, Alameh MG, Bose SK, Zoltick PW, Li H, Zhang R, Cheng AY, Weissman D, Peranteau WH, Mitchell MJ. "Ionizable Lipid Nanoparticles for In Utero mRNA Delivery," Science Advances, online January 13, 2021, DOI: 10.1126/sciadv.aba1028

About Children's Hospital of Philadelphia: Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals, and pioneering major research initiatives, Children's Hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country. In addition, its unique family-centered care and public service programs have brought the 595-bed hospital recognition as a leading advocate for children and adolescents. For more information, visit http://www.chop.edu

Contact: Ashley Moore

Children's Hospital of Philadelphia

(267) 426-6071

Moorea1@chop.edu

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/chop-and-penn-researchers-identify-nanoparticles-that-could-be-used-in-therapeutic-mrna-delivery-before-birth-301207730.html

SOURCE Children's Hospital of Philadelphia



Back to top
| Back to home page
Video

White House Live Stream
LIVE VIDEO EVERY SATURDAY
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Video

LIVE BROADCASTS
Sounds Make the News ®
WAOK-Urban
Atlanta - WAOK-Urban
KPFA-Progressive
Berkley / San Francisco - KPFA-Progressive
WVON-Urban
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
WADO-Spanish
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
WOL-Urban
Washington - WOL-Urban

Listen to United Natiosns News